. Author manuscript; available in PMC: 2010 Jan 1.

Published in final edited form as: Breast Cancer Res Treat. 2008 Jan 20;113(1):31–41. doi: 10.1007/s10549-008-9900-0

Table 3.

Stage-specific inhibition of DMBA-induced mammary alveolar lesions (MAL) by 25(OH)D₃ in mouse mammary organ culture

Treatment	Days of treatment	Number of glands with lesions (%incidence)	%inhibition	Significance (P value^a)
IPAF control	–	0/10	–	–
DMBA	–	13/15 (86.7)	–	–
DMBA + 25(OH)D₃––250 nM	0–4	8/14 (57.1)	34.1	0.1732
DMBA + 25(OH)D₃––250 nM	4–10	3/14 (21.4)	75.3	0.0016
DMBA + 25(OH)D₃––250 nM	0–10	1/15 (6.7)	92.3	<0.0001
DMBA + 1,25(OH)₂D₃––100 nM	4–10	0/15 (0)	100	<0.0001
DMBA + Aspirin––100 nM	0–4	2/15 (13.3)	84.7	0.0003

χ² test, in comparison with DMBA control

1,25(OH)₂D₃ served as a positive control for inhibition of promotion of MAL; aspirin served as a positive control for inhibition of initiation of MAL. 25(OH)D₃ mainly exhibited inhibition at the promotion stage of DMBA-induced MAL, similar to that of 1,25(OH)₂D₃. But treatment during day 1–10 with 25(OH)D₃ generated best inhibitory effect on MAL development